These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20193313)

  • 1. [HIV-1 drug-resistance profiles of treated AIDS patients in Liaoning: genetic characteristics and prevalence].
    Wu SH; Lu CM; Jiang FX; Ma N; E S; Pan S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1273-6. PubMed ID: 20193313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutation of drug resistant gene in HIV/AIDS patients with antiretroviral therapy in Shandong province in 2011].
    Sun XG; Lin B; Su SL; Lin L; Tao XR; Qian YS; Kang DM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Nov; 46(11):982-6. PubMed ID: 23363916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.
    Zhao B; Han X; Dai D; Liu J; Ding H; Xu J; Chu Z; Bice T; Diao Y; Shang H
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1047-53. PubMed ID: 21417755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary drug resistance of HIV-1 infected men who have sex with men in Shenzhen, China].
    Zhao GL; Yu W; Cai YM; Wang F; Hong FC; Jiang WN; Li YL; Peng Y; Zhang CL; Zhang JJ; Feng TJ
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1165-9. PubMed ID: 22883002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.
    Derache A; Maiga AI; Traore O; Akonde A; Cisse M; Jarrousse B; Koita V; Diarra B; Carcelain G; Barin F; Pizzocolo C; Pizarro L; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Sep; 62(3):456-63. PubMed ID: 18556706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
    Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
    Delaugerre C; Braun J; Charreau I; Delarue S; Nere ML; de Castro N; May T; Marchou B; Simon F; Molina JM; Aboulker JP;
    HIV Med; 2012 Oct; 13(9):517-25. PubMed ID: 22416781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the effect of treatment and the status of drug resistance among HIV/AIDS patients treated with highly active antiretroviral therapy in Shandong province].
    Zhang J; Lin B; Lin L; Yang PJ; Fu JH; Li HP; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1108-11. PubMed ID: 18396667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
    Palmer S; Boltz V; Maldarelli F; Kearney M; Halvas EK; Rock D; Falloon J; Davey RT; Dewar RL; Metcalf JA; Mellors JW; Coffin JM
    AIDS; 2006 Mar; 20(5):701-10. PubMed ID: 16514300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.
    de Medeiros RM; Junqueira DM; Matte MC; Barcellos NT; Chies JA; Matos Almeida SE
    J Med Virol; 2011 Oct; 83(10):1682-8. PubMed ID: 21837783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.